UBS Group’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$77.7M Buy
1,337,390
+243,797
+22% +$13.2M 0.01% 1241
2025
Q4
$50.5M Buy
1,093,593
+246,020
+29% +$11M 0.01% 1623
2025
Q3
$30.5M Sell
847,573
-533,280
-39% -$17.7M 0.01% 2115
2025
Q2
$44.9M Buy
1,380,853
+300,457
+28% +$9.85M 0.01% 1621
2025
Q1
$40.8M Buy
1,080,396
+343,835
+47% +$27.5M 0.01% 1673
2024
Q4
$60.3M Buy
736,561
+624,988
+560% +$62.1M 0.01% 1299
2024
Q3
$12.7M Buy
111,573
+15,897
+17% +$1.43M ﹤0.01% 2156
2024
Q2
$7.22M Sell
95,676
-80,402
-46% -$5.47M ﹤0.01% 2510
2024
Q1
$12M Buy
176,078
+10,044
+6% +$696K ﹤0.01% 2117
2023
Q4
$10.4M Buy
166,034
+91,729
+123% +$4.76M ﹤0.01% 2055
2023
Q3
$3.79M Buy
74,305
+28,483
+62% +$1.41M ﹤0.01% 2848
2023
Q2
$2.29M Buy
45,822
+45,478
+13,220% +$2.16M ﹤0.01% 3397
2023
Q1
$12.9K Sell
344
-122,376
-100% -$5.19M ﹤0.01% 7424
2022
Q4
$5.88M Buy
122,720
+122,645
+163,527% +$4.81M ﹤0.01% 2343
2022
Q3
$2K Sell
75
-23,498
-100% -$596K ﹤0.01% 9758
2022
Q2
$513K Sell
23,573
-36,814
-61% -$852K ﹤0.01% 4243
2022
Q1
$1.46M Buy
60,387
+15,152
+33% +$331K ﹤0.01% 3744
2021
Q4
$1.08M Sell
45,235
-76,552
-63% -$1.78M ﹤0.01% 4323
2021
Q3
$3.09M Buy
121,787
+13,884
+13% +$337K ﹤0.01% 3176
2021
Q2
$2.43M Sell
107,903
-7,547
-7% -$155K ﹤0.01% 3402
2021
Q1
$2.28M Buy
115,450
+47,284
+69% +$1.19M ﹤0.01% 3428
2020
Q4
$1.81M Buy
68,166
+67,446
+9,368% +$2.51M ﹤0.01% 3489
2020
Q3
$36K Buy
+720
New +$28.7K ﹤0.01% 5866

Other funds holding PCVX